報價延遲最少15分鐘:2024/06/01 04:37 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.19 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.70/-0.41
|
|
企業價值
28.05M
|
| 資產負債 |
|
每股賬面淨值
0.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/01 04:37 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. |